Bristol-Myers Squibb Company (BMY) Reaches $68.96 52-Week High; Commerce Group (CGI) Sentiment Is 0.57

February 19, 2018 - By Peter Erickson

The stock of Bristol-Myers Squibb Company (NYSE:BMY) hit a new 52-week high and has $74.48 target or 8.00% above today’s $68.96 share price. The 7 months bullish chart indicates low risk for the $112.58 billion company. The 1-year high was reported on Feb, 19 by If the $74.48 price target is reached, the company will be worth $9.01 billion more. The stock decreased 0.03% or $0.02 during the last trading session, reaching $68.96. About 10.55 million shares traded or 47.02% up from the average. Bristol-Myers Squibb Company (NYSE:BMY) has declined 23.19% since February 19, 2017 and is downtrending. It has underperformed by 39.89% the S&P500.

Celadon Group, Inc., through its subsidiaries, provides transportation services between the United States, Canada, and Mexico. The company has market cap of $120.58 million. It operates through three divisions: Asset-Based, Asset-Light, and Equipment Leasing and Services. It has a 50.58 P/E ratio. The Asset-Based segment offers dry van, refrigerated, and flatbed services; cross-border services between the United States and each of Mexico and Canada; intra-Mexico and intra-Canada services; contract services; regional and specialized short haul services; and rail intermodal services.

Since September 6, 2017, it had 1 insider purchase, and 2 insider sales for $646,385 activity. The insider Caldarella Joseph C sold $560,400. On Tuesday, December 12 the insider Lynch Thomas J. Jr. sold $335,172. Samuels Theodore R. II had bought 4,000 shares worth $249,187.

Bristol-Myers Squibb Company discovers, develops, licenses, makes, markets, and distributes biopharmaceutical products worldwide. The company has market cap of $112.58 billion. The firm offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection . It has a 113.05 P/E ratio. The Company’s products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma.

Investors sentiment increased to 1.03 in Q3 2017. Its up 0.08, from 0.95 in 2017Q2. It increased, as 62 investors sold Bristol-Myers Squibb Company shares while 519 reduced holdings. 137 funds opened positions while 460 raised stakes. 1.11 billion shares or 0.68% more from 1.10 billion shares in 2017Q2 were reported. Primecap Mgmt Ca holds 6.37 million shares. Philadelphia stated it has 24,305 shares. Hengehold Management Ltd Limited Liability Company stated it has 17,993 shares. Burt Wealth Advsr reported 6,092 shares stake. Hyman Charles D reported 194,327 shares. Stonebridge Ltd Liability holds 1.24% or 79,364 shares. Schmidt P J Inv Mngmt Inc invested in 1.59% or 83,506 shares. Hilltop Hldgs reported 0.47% in Bristol-Myers Squibb Company (NYSE:BMY). Puzo Michael J owns 11,200 shares. Strs Ohio stated it has 1.53M shares or 0.42% of all its holdings. Mitsubishi Ufj Ltd invested 0.27% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Sand Hill Glob Lc, a California-based fund reported 3,968 shares. Invest House Ltd Com has 41,029 shares for 0.34% of their portfolio. Planning Advisors invested in 39,761 shares. Mutual Of America Cap Mngmt Limited Liability Corporation owns 262,838 shares.

Among 19 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 7 have Buy rating, 3 Sell and 9 Hold. Therefore 37% are positive. Bristol-Myers Squibb Company has $80 highest and $45 lowest target. $63.33’s average target is -8.16% below currents $68.96 stock price. Bristol-Myers Squibb Company had 73 analyst reports since July 28, 2015 according to SRatingsIntel. As per Friday, September 22, the company rating was maintained by Piper Jaffray. The firm has “Buy” rating by Jefferies given on Monday, December 19. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Hold” rating by Piper Jaffray on Thursday, October 26. Cowen & Co maintained the shares of BMY in report on Monday, July 10 with “Hold” rating. Piper Jaffray upgraded the shares of BMY in report on Monday, August 24 to “Underweight” rating. UBS maintained the shares of BMY in report on Friday, October 6 with “Buy” rating. The firm has “Hold” rating given on Friday, October 28 by Deutsche Bank. The firm earned “Buy” rating on Tuesday, September 20 by Citigroup. The company was maintained on Friday, February 16 by Citigroup. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Sell” rating by Societe Generale on Wednesday, April 6.

The stock increased 1.16% or $0.05 during the last trading session, reaching $4.35. About 512,362 shares traded or 14.77% up from the average. Celadon Group, Inc. (CGI) has declined 74.33% since February 19, 2017 and is downtrending. It has underperformed by 91.03% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Peter Erickson

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: